Last reviewed · How we verify
Fat/Inflammation effects
This is a research focus area rather than a specific drug, targeting the reduction of fat accumulation and inflammatory markers associated with metabolic dysfunction.
This is a research focus area rather than a specific drug, targeting the reduction of fat accumulation and inflammatory markers associated with metabolic dysfunction. Used for Type 2 diabetes mellitus, Metabolic syndrome with obesity.
At a glance
| Generic name | Fat/Inflammation effects |
|---|---|
| Sponsor | German Diabetes Center |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
The German Diabetes Center's work on fat/inflammation effects likely encompasses therapeutic strategies aimed at reducing visceral adiposity and systemic inflammation, which are key drivers of insulin resistance and type 2 diabetes. This may involve multiple mechanistic approaches including modulation of adipose tissue metabolism, reduction of pro-inflammatory cytokines, or improvement of metabolic endotoxemia.
Approved indications
- Type 2 diabetes mellitus
- Metabolic syndrome with obesity
Common side effects
Key clinical trials
- Screening and Multiple Intervention on Lung Epidemics (PHASE2)
- Comparing a Healthy Beef-Centric Diet to a Healthy U.S.-Style Diet on Metabolic Health Outcomes in Pre-Diabetic Adults (NA)
- Non-Pharmacological Interventions for Neurotoxicity in Hematologic Patients Receiving CAR-T Therapy (NA)
- Complex Effects of Dietary Manipulation on Metabolic Function, Inflammation and Health (NA)
- Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
- Determine How Consumption of Dairy Fat Fractions Rich in Phospholipids and Proteins Influence Inflammation in the Fed State-Phase 1 (NA)
- Determine How Consumption of Dairy Fat as Cheese Influences Inflammation-Phase 2 (NA)
- Molecular Investigation of GENetic Factors in Cardiovascular and Immune-related Traits and Diseases Using a BIOresource of Healthy Volunteers (GENBIO)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fat/Inflammation effects CI brief — competitive landscape report
- Fat/Inflammation effects updates RSS · CI watch RSS
- German Diabetes Center portfolio CI